LENZ Therapeutics Inc (LENZ)

Currency in USD
16.89
-0.73(-4.14%)
Closed·
17.01+0.12(+0.71%)
·
LENZ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.2617.46
52 wk Range
15.7050.40
Key Statistics
Prev. Close
17.62
Open
17.2
Day's Range
16.26-17.46
52 wk Range
15.7-50.4
Volume
810.88K
Average Volume (3m)
1.19M
1-Year Change
-46.04%
Book Value / Share
6.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LENZ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
53.71
Upside
+218.02%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period

LENZ Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

LENZ Therapeutics Inc Earnings Call Summary for Q3/2025

  • LENZ Therapeutics reported Q3 2025 net loss of $0.59 per share with operating expenses up 44% to $31.4M, causing stock to drop 9.38% to $25.42 despite VIZ eye drop launch
  • VIZ, LENZ's FDA-approved treatment for presbyopia, secured over 5,000 prescriptions in its first month with full pharmacy availability expected by mid-November
  • SG&A expenses surged 116% quarter-over-quarter to $27.6M while R&D expenses decreased 58% to $3.8M; company maintains strong $324M cash position
  • Management projects $80-100M commercial spend for 2026 and plans Q1 2026 direct-to-consumer campaign featuring Sarah Jessica Parker
Last Updated: 05/11/2025, 15:32
Read Full Transcript

Compare LENZ to Peers and Sector

Metrics to compare
LENZ
Peers
Sector
Relationship
P/E Ratio
−9.0x−11.0x−0.6x
PEG Ratio
−0.19−0.170.00
Price/Book
2.7x2.2x2.6x
Price / LTM Sales
30.2x6.3x3.2x
Upside (Analyst Target)
217.8%20.4%41.8%
Fair Value Upside
Unlock−1.3%5.1%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 53.71
(+218.02% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy56.00+231.56%-Maintain27/10/2025
Piper Sandler
Buy67.00+296.68%51.00Maintain10/10/2025
H.C. Wainwright
Buy56.00+231.56%48.00Maintain22/08/2025
H.C. Wainwright
Buy56.00+231.56%48.00Maintain04/08/2025
H.C. Wainwright
Buy56.00+231.56%48.00Maintain01/08/2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -2.11%
Dividend Yield
-
Industry Median 0.67%
Annualised payout
-
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.59 / -0.40
Revenue / Forecast
12.50M / --
EPS Revisions
Last 90 days

People Also Watch

11.03
SPRY
-2.90%
35.41
IDYA
-0.25%
20.41
DYN
-1.78%
1.520
ELDN
-7.32%

FAQ

What Is the LENZ Therapeutics (LENZ) Share Price Today?

The live LENZ Therapeutics share price today is 16.89

What Stock Exchange Does LENZ Therapeutics (LENZ) Trade On?

LENZ Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for LENZ Therapeutics?

The stock symbol (also called a 'ticker') for LENZ Therapeutics is "LENZ."

What Is the Current LENZ Therapeutics Market Cap?

As of today, LENZ Therapeutics market capitalisation is 528.49M.

What Is LENZ Therapeutics's (LENZ) Earnings Per Share (TTM)?

The LENZ Therapeutics EPS is currently -2.11 (Trailing Twelve Months).

Is LENZ a Buy or Sell From a Technical Analyst Perspective?

Based on today's LENZ Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has LENZ Therapeutics Stock Split?

LENZ Therapeutics has split 1 times. (See the LENZ stock split history page for full effective split date and price information.)

How Many Employees Does LENZ Therapeutics Have?

LENZ Therapeutics has 11 employees.

What is the current trading status of LENZ Therapeutics (LENZ)?

As of 24 Dec 2025, LENZ Therapeutics (LENZ) is trading at a price of 16.89, with a previous close of 17.62. The stock has fluctuated within a day range of 16.26 to 17.46, while its 52-week range spans from 15.70 to 50.40.

What Is LENZ Therapeutics (LENZ) Price Target According to Analysts?

The average 12-month price target for LENZ Therapeutics is USD53.71429, with a high estimate of USD62 and a low estimate of USD36. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +218.02% Upside potential.

What Is the LENZ Premarket Price?

LENZ's last pre-market stock price is 17.42. The pre-market share volume is 3,430.00, and the stock has decreased by -0.20, or -1.14%.

What Is the LENZ After Hours Price?

LENZ's last after hours stock price is 17.01, the stock has decreased by 0.12, or 0.71%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.